Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports
Authors:
Open Access
- 9 May 2020
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 8 (8) , 1458-1460
Abstract
Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.Keywords
This publication has 11 references indexed in Scilit:
- Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case seriesBritish Journal of Dermatology, 2019
- Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case seriesDermatologic Therapy, 2019
- Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With DupilumabJAMA Dermatology, 2019
- Rosacea associated with dupilumab therapyJournal of Dermatological Treatment, 2019
- Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case seriesBritish Journal of Dermatology, 2019
- Psoriasis induced by dupilumab therapyClinical and Experimental Dermatology, 2019
- Erythrodermic presentation of psoriasis in a patient treated with dupilumabJAAD Case Reports, 2018
- Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two casesThe Journal of Dermatology, 2018
- Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysisInternational Immunopharmacology, 2018
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016